CN113855729A - Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens - Google Patents
Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens Download PDFInfo
- Publication number
- CN113855729A CN113855729A CN202111275085.0A CN202111275085A CN113855729A CN 113855729 A CN113855729 A CN 113855729A CN 202111275085 A CN202111275085 A CN 202111275085A CN 113855729 A CN113855729 A CN 113855729A
- Authority
- CN
- China
- Prior art keywords
- parts
- mixture
- weight
- astragalus
- honeysuckle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Sustainable Development (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound astragalus polysaccharide particle for preventing and treating avian influenza, which can effectively solve the problem of drug use of avian influenza and adopts the technical scheme that the compound astragalus polysaccharide particle comprises the following components in parts by weight: 20-30 parts of astragalus membranaceus, 10-20 parts of honeysuckle, 15-35 parts of radix isatidis, 10-20 parts of radix achyranthis bidentatae, 10-20 parts of angelica sinensis, 10-30 parts of fructus forsythiae, 20-30 parts of ternate buttercup root and 5-15 parts of semen momordicae, and the raw materials are extracted and concentrated by a modern process, and then added with auxiliary materials to prepare granules, wherein the auxiliary materials are one or a mixture of more than two of starch, powdered sugar and dextrin. Meanwhile, the preparation method is simple, low in cost and convenient to use, has a good effect of preventing avian influenza of poultry, and is suitable for large-scale popularization and use.
Description
Technical Field
The invention belongs to the technical field of pharmacy, and particularly relates to a compound astragalus polysaccharide particle combined medicine for preventing and treating avian influenza and a preparation method thereof.
Background
Avian influenza is a short name of avian influenza and has the disease characteristics of chicken avian influenza: firstly, the clinical symptoms are complex, and the clinical symptoms are often mixed with infectious bronchitis, infectious laryngopathy, colibacillosis and the like; secondly, the morbidity and mortality are related to strains, gender, environment, complications and secondary infection of the chicken flocks, for example, the avian influenza virus invades mucous membrane, which is beneficial to secondary colibacillosis, so that the hemagglutinin action of the avian influenza virus is enhanced, and the morbidity and mortality of the chicken flocks are increased; thirdly, the avian influenza virus has a plurality of serotypes, the cross protection among the types is weak, and the toxicity difference of different strains of the same serotype is large; fourthly, the avian influenza virus has high variation frequency, is easy to have pathogenicity variation and antigen drift and transformation, and the current situation of the harm and prevention of the avian influenza of the chicken is as follows: firstly, avian influenza is found for over 100 years, human beings do not master specific prevention and treatment methods, and can only prevent the spread of the avian influenza by a method of disinfection, isolation and mass slaughtering of livestock, thereby causing great harm to the chicken industry. Secondly, the immunity defense system of the organism is firstly destroyed after the poultry are infected with the avian influenza, so that the immunity and the self-repairing ability of the organism are lost; the western antiviral drugs have partial antagonism on virus particles after being clinically used, but have toxic and side effects on body cells of the poultry, and the veterinary clinical western antiviral drugs have not ideal effect on preventing and treating avian influenza of the poultry. Fourthly, after the western medicine antiviral drugs are used in the poultry raising process, serious problems such as food safety and the like are caused, so that the human health and the prevention and control safety of human diseases are influenced, and the western medicine antiviral drugs are definitely not allowed to be used for preventing and controlling the bird flu in the livestock and poultry in China, so that no antiviral veterinary drug exists in the aspect of preventing and controlling the bird flu at present. The research shows that the clinical effect of some Chinese veterinary medicines such as astragalus, honeysuckle, radix isatidis, momordica cochinchinensis and the like for preventing and treating the avian influenza of the poultry is good in clinical prevention and treatment research and exploration of the avian influenza of the poultry by human beings, and the research also shows that the Chinese veterinary medicines such as the astragalus and the like not only have strong clinical antiviral capacity, but also have the effects of enhancing the immunity and disease resistance of the organism and improving the self-repairing capacity of the organism. The traditional Chinese veterinary medicine is relatively simple in processing technology and relatively rough in processing, and is mostly prepared from simple coarse powder or fine powder or is directly mixed into poultry feed or drinking water after being decocted traditionally, so that the effective ingredients of the traditional Chinese veterinary medicine cannot be sufficiently and effectively absorbed and utilized, and the clinical application effect is not ideal. Therefore, improvement of drugs for preventing and treating avian influenza is a problem which needs to be solved urgently at present.
Disclosure of Invention
In order to solve the defects of the prior art, the invention aims to provide the compound astragalus polysaccharide granules for preventing and treating the avian influenza, which can effectively solve the problem of medication for preventing and treating the avian influenza.
The technical scheme of the invention is as follows:
is prepared from the following components in percentage by weight: 20-30 parts of astragalus membranaceus, 10-20 parts of honeysuckle, 15-35 parts of isatis root, 10-20 parts of radix achyranthis bidentatae, 10-20 parts of angelica sinensis, 10-30 parts of fructus forsythiae, 20-30 parts of ternate buttercup root and 5-15 parts of semen momordicae, and the traditional Chinese medicine is prepared by the following steps:
(1) the astragalus, the honeysuckle, the isatis root, the angelica, the forsythia and the radix ranunculi ternate are respectively subjected to impurity removal and air drying, the standard weight is respectively weighed according to the formula, and the mixture is respectively crushed into coarse powder mixture with the granularity of 40-60 meshes for later use;
(2) weighing the achyranthes bidentata in a standard weight, and crushing the achyranthes bidentata into coarse powder with the granularity of 40-60 meshes for later use;
(3) removing shells of the semen momordicae, removing impurities by using semen momordicae, and weighing standard weight for later use;
(4) adding water into the mixture of the astragalus, the honeysuckle, the isatis root, the angelica, the fructus forsythiae and the radix ranunculi ternate in the step (1) for leaching for three times, soaking the mixture in water with the weight being 12 times that of the honeysuckle for 30-40 min for the first leaching, decocting the mixture for 1.5h with slow fire, and filtering the decoction to obtain a first filtrate; adding water with the weight being 10 times that of the mixture into the primary filtration dregs for secondary leaching, decocting the mixture for 1.5 hours with slow fire, and filtering the mixture to obtain a second filtrate; adding water with the weight 10 times that of the mixture into the residue obtained after the second filtration for carrying out third leaching, decocting with slow fire for 1h, filtering to obtain a third filtrate, combining the first filtrate, the second filtrate and the third filtrate, concentrating to obtain a concentrated solution with the ratio of 1:1, precipitating with absolute ethyl alcohol with the volume 4 times that of the concentrated solution, and drying the precipitate to obtain a mixture of astragalus polysaccharide and the like;
(5) adding water into the coarse achyranthes bidentata powder obtained in the step (2), leaching for 2 hours at 100 ℃ at a material-liquid ratio of 1:15, adding ethanol with the mass concentration of 95% and 5 times of the weight of achyranthes bidentata into the leaching solution, leaching for 2 times, each time for 2 hours, combining filtrates, concentrating, and drying to obtain achyranthes bidentata polysaccharide;
(6) pressing the semen momordicae in the step (3) in an extrusion type frost making machine, controlling the temperature to be 100 ℃, stopping pressing when the oil output reaches 17-20%, and crushing and uniformly mixing the medicine residues to obtain semen momordicae frost;
(7) fully mixing the extracts respectively prepared in the step (4), the step (5) and the step (6) to obtain an extraction mixture;
(8) pulping according to a granule preparation process, adding auxiliary materials into the extract mixture obtained in the step (7), and filling the extract mixture into a one-step low-temperature boiling granulator to prepare granules to obtain finished products. The auxiliary material is one or the mixture of more than two of starch, powdered sugar and dextrin.
The specific implementation mode is as follows:
the following examples further illustrate the embodiments of the present invention in detail.
Example 1:
the invention, when embodied, is made from the following weight: 3. the compound astragalus polysaccharide particle disclosed by the invention in claim 1 is characterized by comprising the following components in parts by weight: 20 parts of astragalus membranaceus, 10 parts of honeysuckle, 15 parts of isatis root, 10 parts of achyranthes root, 10 parts of Chinese angelica, 10 parts of fructus forsythiae, 20 parts of ternate buttercup root and 5 parts of semen momordicae are used as raw material medicaments, and a finished product is prepared according to the steps of the technical scheme.
Example 2:
the invention, when embodied, is made from the following weight: 30 parts of astragalus membranaceus, 20 parts of honeysuckle, 35 parts of isatis root, 20 parts of achyranthes root, 20 parts of Chinese angelica, 30 parts of fructus forsythiae, 30 parts of ternate buttercup root and 15 parts of semen momordicae. The finished product is prepared according to the steps of the technical scheme.
Example 3:
the invention, when embodied, is made from the following weight: 25 parts of astragalus, 15 parts of honeysuckle, 25 parts of isatis root, 15 parts of achyranthes root, 15 parts of angelica, 20 parts of forsythia, 25 parts of ternate buttercup root and 10 parts of semen momordicae. The finished product is prepared according to the steps of the technical scheme.
The formula of the invention comprises the following components:
the compound astragalus polysaccharide particle comprises the following components: astragalus, honeysuckle, radix isatidis, achyranthes, angelica, forsythia, radix ranunculi ternati and semen momordicae:
astragalus root: in recent years, research on Astragalus Polysaccharide (APS) has been reported, wherein Astragalus contains various effective components such as polysaccharide, saponin, flavone, amino acid and trace elements, and the active components have the effect of promoting antibody generation and immune reaction. The astragalus polysaccharide is one of the main active ingredients of astragalus and is obtained by high-tech extraction and separation. The astragalus polysaccharide is a main component of astragalus, can promote the metabolism of organisms, resist fatigue, promote the update of serum and liver protein, enhance and regulate the immune function of the organisms, promote an interferon system, improve the disease resistance of the organisms, slightly inhibit cytopathic effect caused by various viruses such as influenza virus and the like, protect mice infected by the influenza virus and also have a wider antibacterial effect;
honeysuckle flower: clear heat and remove toxicity, disperse wind-heat. Can be used for treating carbuncle, furuncle, sore throat, erysipelas, toxic heat, dysentery, wind-heat type common cold, epidemic febrile disease, and fever. According to modern medical research, honeysuckle has the effects of resisting various microorganisms, resisting inflammation, relieving inflammation, resisting endotoxin, exciting central nerves, strengthening immune function and the like;
radix isatidis: clear heat and remove toxicity, cool blood and relieve sore throat. Can be used for treating toxic heat, speckle, crimson dark tongue, mumps, pharyngitis, erysipelas, fever with swollen head, erysipelas, and carbuncle. Research shows that the isatis root (or the rhizome of isatis tinctoria) extract plays a role in inhibiting and killing avian influenza A virus and avian influenza B virus by limiting virus division, the aqueous solution of the extract has an inhibiting effect on common cold virus, an inhibiting and killing effect on epidemic meningitis B virus, isatis tinctoria root also has an inhibiting effect on various bacteria, and the water extract has inhibiting effects on bacillus subtilis, staphylococcus aureus, sarcina, escherichia coli, typhoid bacillus, paratyphoid bacillus, dysentery (shigella, frambelliferae) bacillus, enteritis bacillus and the like to different degrees;
achyranthes root: promoting blood circulation, dredging channels, nourishing liver and kidney, strengthening tendons and bones, inducing diuresis, treating stranguria, and inducing fire (blood) to descend. Modern research: has antiinflammatory, analgesic, and immunity enhancing effects. Radix Achyranthis contains triterpenoid saponin (prepared by hydrolyzing to oleanolic acid and sugar), ecdysterone, inocosterone, and radix Achyranthis bidentatae sterone, and polysaccharides. The total saponins of achyranthes bidentata have obvious exciting effect on uterine smooth muscle, the achyranthes bidentata benzene extract has obvious antifertility, anti-implantation and anti-early pregnancy effects, and the active ingredient for antifertility is ecdysteroid;
chinese angelica: tonify blood, activate blood, regulate menstruation, alleviate pain, moisten intestines to relieve constipation. Modern research: radix Angelicae sinensis also has effects of strengthening body resistance, resisting cancer, enhancing immunity, improving circulation, resisting inflammation, relieving pain, replenishing blood, nourishing lung, protecting liver, promoting bile flow, protecting kidney, removing toxic substance, warming uterus, and increasing egg production. The angelica and the sodium ferulate and the angelica polysaccharide which are extracted from the angelica have obvious stimulation effect on a mononuclear-macrophage system and have immune regulation and recovery effect on organisms with low immune function. The angelica has promotion effect on lymphocyte transformation of healthy organisms;
fructus forsythiae: clear heat and remove toxicity, resolve swelling and dissipate nodulation. Can be used for treating carbuncle, cellulitis, scrofula, acute mastitis, erysipelas, wind-heat type common cold, early epidemic febrile disease, warm heat entering nutrient system, hyperpyrexia, polydipsia, coma, stranguria, and anuresis; modern research: fructus forsythiae has effects of relieving fever and inflammation, resisting bacteria, resisting virus, removing toxic substance (its antibacterial component is forsythol, fructus forsythiae lipoid glycoside A and volatile oil. fructus forsythiae lipoid glycoside B has antifungal effect. its volatile oil has effects of inhibiting influenza virus remarkably, also has effects of resisting endotoxin.), protecting liver and antiemetic, antiallergic etc., it is used for treating various infectious diseases clinically, including virus, bacterial infection and fever, such as common cold, upper respiratory infection, bronchitis, pneumonia, cholecystitis, urinary tract infection, sore and furuncle etc., it is suitable for use regardless of acute or chronic. It can be used for treating bacteria, viruses, and fungi. And has endotoxin removing effect. The effect can be enhanced by using the antibiotic simultaneously;
radix ranunculi ternati: resolve phlegm and dissipate nodulation, remove toxicity and relieve swelling. Modern research: ranunculus ternatus thumb contains ranunculalin, protoanemonin, arachidic acid, octadecyl myristate, stigmasterol, beta-sitosterol, glucose, arabinose, galactose, and oil and plant alkaloid. Has strong antibacterial, anti-tumor, anti-inflammatory, body condition improving and disease resistance enhancing effects;
semen momordicae: counteract toxic pathogen and cure sore, resolve swelling and dissipate nodulation. Modern research: contains momordica saponin, momordica acid, momordica element, oleanolic acid, sterol, amino acid, 35.72% of oil, 30.59% of protein, trehalose, etc. Semen Momordicae saponin has antiinflammatory, blood pressure lowering, and anti-hemolytic effects.
Example 4: clinical trial research of compound astragalus polysaccharide particles on prevention and treatment of avian influenza of chickens
1 materials and methods
1.1 test materials
Compound astragalus polysaccharide particles; prepared by Henan Narison biological pharmaceutical industry Co Ltd according to the preparation process and steps, and the batch number is as follows: 2018041601, respectively; amantadine hydrochloride: purchased from pharmaceutical chemical company limited, Hubei, lot number: 2018032002
1.2 test Chicken farm selection and grouping
The test is arranged in three closed chicken houses at different disease stages of 45 weeks old in a commercial Roman brown-shell egg chicken farm of certain poultry company in south Yang, and Avian Influenza (AI) subtype H9 is confirmed by collecting disease materials, carrying out AGP and HI tests on blood samples, carrying out bacterial culture, virus separation and clinical symptom combination and pathological anatomy examination in advance. The number of the pigs is 10128, which is totally randomly divided into 5064 test groups and 5064 control groups, the number of the pigs is 10243, which is totally randomly divided into 5120 control groups and 5123 control groups, the number of the pigs is 10136, which is totally randomly divided into 5068 test groups and 5068 control groups. The three tested chickens are all 45-week old roman brown commercial generation laying hens. The stage I chicken flock is the 3 rd day old of the disease, the stage II chicken flock does not have symptoms (is in the latent period), and the stage III chicken flock is the 14 th day old after the disease.
1.3 Breeding management
Each farm animal is subjected to feeding management according to a normal feeding management method, the feeding management conditions are the same, and the management method of each test group and the corresponding control group is also the same.
1.4 protocol
1.4.1 the control groups use 160mg/L amantadine hydrochloride drinking water, the test groups use compound astragalus polysaccharide particles, the dose of the test group I is 200mg/L, the doses of the test group II and the test group III are 160mg/L, and the continuous medication is carried out for 14 days.
1.4.2 observe and record the mental, ingestion, drinking water, feces, morbidity and mortality of all the Roman brown layer chickens every day.
1.4.3 during the experiment period, eggs laid by the experimental group and the control group of the henhouse I, II and III are all strictly scrapped and harmlessly treated, all the chickens in the three control groups using the amantadine hydrochloride are strictly tracked and monitored after the experiment is finished, all the eggs containing amantadine hydrochloride drug residues are strictly scrapped and harmlessly treated, and after the body blood, the liver, the muscle and the excrement of the experimental three control groups of the laying hens are detected to be free of amantadine hydrochloride and metabolic residues thereof, the experimental period is considered to be completely finished.
1.5 changes in epidemic during the test
In this test, the control group of the group II Romanbrown layer group began to develop disease in both groups on day 4 of the test, and the control group of the group III Romanbrown layer group had relapsed avian influenza H9 subtype on day 6 of the test, i.e., 20 days after the initial onset.
2 results and analysis
2.1 the observation of the effect of compound astragalus polysaccharide granules on preventing and treating avian influenza is shown in table 1:
table 1: observation test result of bird flu prevention and treatment effect of compound astragalus polysaccharide particles
As can be seen from the test results, the yield level of each test group is equivalent to that of the control group (P >0.05) at the beginning of the test, each test group is obviously superior to the corresponding control group in all indexes in the test period, each test group is compared with the corresponding control group, the test group in the department I and the control group show very significant difference in morbidity (P <0.01), the test group in the department II and the control group show basically the same performance (P >0.05), and the test group in the department III and the control group show significant difference (P < 0.05); the difference between the test group of the house I and the control group is significant (P <0.01), and the difference between the test group of the house II and the test group of the house III and the control group is insignificant (P > 0.05); the differences of the test groups of three houses of a house I, a house II and a house III from the control group are extremely obvious (P is less than 0.01) in the reduction range of the laying rate, especially the difference of the test group of the house I from the control group is most obvious, and the laying rate of the test group is directly increased by 23.43 percent; the performance differences of the test groups of three houses of the I house, the II house and the III house and the control group are obvious in the abnormal egg rate (P is less than 0.05).
2.2 Effect of Compound Astragalus polysaccharides granule on avian influenza immune function of egg-laying hen
Table 2: influence of compound astragalus polysaccharide particles on level of immune antibody and spleen coefficient of avian influenza of laying hens
(data in the same column marked with different lower case letters to show significant difference (P <0.05), different upper case letters to show significant difference (P <0.01), and the same letters or the same marked letters to show insignificant difference (P > 0.05).)
As can be seen from Table 2, the levels of the compound astragalus polysaccharide particles added to the feed of the laying hens at different levels can improve the serum immune antibody level of the avian influenza of the laying hens at different degrees, and the groups I, II, III, IV and V are all obviously higher than the control group (P <0.05), but the groups have no obvious difference (P > 0.05). The spleen coefficients can be improved to different degrees by adding compound astragalus polysaccharide particles with different levels into the feed of the laying hens, and the groups I, II, III, IV and V are all obviously higher than the control group (P <0.05), but the groups have no obvious difference (P > 0.05).
3 conclusion
The following conclusions can be obtained by combining the results of the prevention and treatment test and the detection of the influence on the avian influenza immune antibody level and spleen coefficient of the laying hens with the local epidemic characteristics of the disease:
3.1 the compound astragalus polysaccharide particles are added to prevent and treat the avian influenza in the early, middle and later stages, the mortality rate and the laying rate of the chicken can be greatly reduced, and the compound astragalus polysaccharide particles have obvious antiviral and anti-inflammatory effects; is obviously superior to amantadine hydrochloride.
3.2 the resistant chickens with the primary disease obviously can obtain certain immunity to the disease, but because the disease destroys the immune system of the chickens, a plurality of chickens usually relapse the disease to different degrees after the initial 20-30 days, and if the compound astragalus polysaccharide particles are added after the initial disease, the relapse of the disease can be effectively prevented.
3.3 the use of compound astragalus polysaccharide granules for preventing and treating the disease is obviously superior to amantadine hydrochloride in the aspects of reducing laying rate and recovering eggshell quality.
3.4 adding compound astragalus polysaccharide particles with different levels into the feed of the laying hens, and obviously improving the level of avian influenza antibody of the laying hens. Thereby effectively reducing the infection rate and incidence rate of the laying hens to the avian influenza and improving the defense skill of the laying hens to the avian influenza.
4. The efficacy and action of the compound astragalus polysaccharide particles
4.1 the traditional Chinese medicine considers that the astragalus has the drug effects of tonifying middle-jiao and Qi, strengthening exterior and invigorating yang, promoting tissue regeneration, and strengthening interior and consolidating foundation. The compound astragalus polysaccharide particle is prepared by refining and extracting astragalus, and mainly comprises various immunopotentiating substances such as astragalus polysaccharide I, astragalus polysaccharide II and the like, and extracts such as honeysuckle, isatis root, angelica, forsythia and the like, and components such as achyranthes polysaccharide, ternate buttercup root polysaccharide, cochinchina momordica seed cream and the like which support each other, can stimulate an organism to generate a large amount of leukocyte interferon, phagocyte and lymphocyte, can strengthen humoral immunity approaches in vivo, generate a large amount of immunoglobulin and complement, improve microcirculation, effectively regulate and enhance humoral immunity and cellular immunity of the organism, improve the immune function of the organism, generate interference, phagocytosis and combination effects on viruses, kill viruses and bacteria in various approaches, have the effects of clearing heat, detoxifying, regulating metabolic dysfunction of the organism and enhance the disease resistance of poultry.
4.2 the effect of the compound astragalus polysaccharide granules is as follows: has the functions of clearing away heat and toxic material, strengthening body resistance, eliminating evil, invigorating spleen and kidney, benefiting vital energy, nourishing blood, resisting virus and bacteria, inducing body to produce interferon, promoting antibody formation, strengthening body's immunity and repairing capacity of various systems, resisting disease, promoting growth, resisting stress, etc. Especially has the best effect of preventing and treating avian influenza of poultry.
4.2.1 broad-spectrum antiviral application: the compound astragalus polysaccharide particle is a broad-spectrum antiviral and interferon inducer, and can stimulate the functions of macrophages and T cells, increase the number of E-ring forming cells, induce cytokines and promote interleukin induction. So that the animal body can produce endogenous interferon, thereby achieving the aim of resisting virus. Can be used for treating viral infectious diseases such as avian influenza and infectious bursal disease. The compound astragalus polysaccharide particles can prevent cold and reduce the morbidity by more than 80 percent, and the astragalus polysaccharide can reduce the morbidity by more than 90 percent by combining with extracts of honeysuckle, isatis root, angelica, forsythia and the like, achyranthes polysaccharide, ternate buttercup root polysaccharide and momordica cochinchinensis cream.
4.2.2 application of enhancing vaccine immunity: the compound astragalus polysaccharide particles have the effects of enhancing the name and the epidemic capacity of organisms, greatly enhancing the immunity of vaccine, having good protection effect on vaccine, and according to research reports that the astragalus polysaccharide can enhance the serum body titer of Marek's disease vaccine. The compound astragalus polysaccharide particles can be used together with NDV and IV vaccines to improve the serum HI antibody titer of immunized chickens, and can be matched with the compound astragalus polysaccharide particles to enhance the chicken coccidian immunity protection capability when the coccidian vaccines are used.
4.2.3 effects on liver: the compound astragalus polysaccharide granule can promote the synthesis of DNA and RNA of liver cells, relieve pathological changes caused by hepatotoxic substances, enhance the detoxification function of the liver and protect the liver cells. Has good prevention and treatment effects on chicken fatty liver, hydropericardium hepatitis syndrome, hepatosplenopathy and hepatitis splenomegaly syndrome, and can improve the feed intake of livestock and poultry, thereby promoting the growth and development of livestock and poultry.
4.2.4 action on kidneys: the compound astragalus polysaccharide granule can improve renal cell metabolism and renal function, reduce blood creatinine level, and relieve renal failure after nephrectomy. Has good prevention and treatment effects on nephrotic syndrome, acute renal failure, nephrotic syndrome, kidney swelling, urate deposition and other symptoms. Meanwhile, the kidney-invigorating function can be achieved, and the growth and breeding functions of livestock and poultry can be exerted.
4.2.5 improvement of reproductive performance: the compound astragalus polysaccharide particles have the functions of stabilizing cells, resisting aging, resisting free radicals and peroxidation, and can obviously improve the service life and the use efficiency of breeding hens when used regularly for a long time. In addition, the compound astragalus polysaccharide particles have the gonadotropic effect, and can thicken endometrium, enlarge uterine cavity and increase the weight of uterine horn and ovary of female animals. The compound astragalus polysaccharide particles can also improve the reproductive performance of male animals, and can obviously improve the activity of sperms, the survival rate of the sperms, the density of the sperms and the like.
4.2.6 is the fourth need for chick health: currently, young bird health care is mostly made in three aspects: (ii) a vaccine for preventing viral diseases. ② antibiotics for preventing bacterial diseases. And thirdly, nutrient substances for enhancing physique and immunity. Through long-term practical research, the 'fourth requirement' of the young poultry health care is found to be the compound astragalus polysaccharide particles while the three health care requirements of the young poultry are met. It not only can fully play the three health-care functions, but also can meet the requirements of health-care of young poultry, no drug residue and full play of the growth potential of young poultry.
4.2.7 has effects in improving nutrient utilization and promoting animal growth. The compound astragalus polysaccharide granule contains various nutrient substances such as amino acid, vitamin, trace elements and the like, and Unknown Growth Factors (UGF). The feed additive can obviously improve the growth speed of livestock and poultry, improve the body resistance and improve the quality and the yield of eggs.
5 clinical application of the compound astragalus polysaccharide particles
5.1 is used for preventing and treating low-pathogenicity avian influenza of poultry and effectively preventing and controlling high-pathogenicity avian influenza by immunity.
5.2 effectively treating and preventing the low immune function of the poultry body (atrophy of organs such as thymus, liver, kidney, bursa of fabricius and the like);
5.3 has special effects on slow growth speed of meat poultry, low feed intake, poor uniformity, no egg laying peak of egg-laying poultry or egg drop caused by unknown reasons, intractable watery diarrhea, rectocele and the like.
5.4 has protection and synergistic effect on the vaccine, obviously improves the immunity valence, and can be used together with the vaccine.
5.5 the combined use with anticoccidial drugs can obviously improve the anticoccidial index.
5.6 can be used for preventing and treating various viral diseases of livestock and fowl, such as circovirus, porcine reproductive and respiratory syndrome, influenza, pseudorabies, viral diarrhea, recurrent asthma, and unknown hyperpyrexia.
The invention has the conclusion that the invention has:
6.1 the compound astragalus polysaccharide granule has good clinical application effect, scarce granule market, higher market competitiveness than popular powder, high technological content and large added value.
6.2 the compound astragalus polysaccharide particles adopt the process of one-step granulation of particle preparation by ultralow temperature boiling, have distinct advantages, are convenient for storage and clinical application, and are easier to cut into the market.
6.3 the compound astragalus polysaccharide particles have stable properties, excellent water solubility, no toxicity, no harm and no medicine residue.
6.4 the market of raw materials is sufficient, the process operation is convenient, the stirring and the drinking are convenient and uniform, and the product development prospect is wide.
In a word, after years of research, clinical tests and practice summarization, the formula of the compound astragalus polysaccharide particle is feasible and effective, and is worthy of popularization, the compound astragalus polysaccharide particle is effectively used for preventing and treating virus diseases such as chicken avian influenza and the like, and the successful research and development of the compound astragalus polysaccharide particle can create great economic benefits and far-reaching social benefits for society.
Claims (7)
1. A compound astragalus polysaccharide particle for preventing and treating avian influenza of chickens is characterized by comprising the following components in parts by weight: 20-30 parts of astragalus membranaceus, 10-20 parts of honeysuckle, 15-35 parts of isatis root, 10-20 parts of radix achyranthis bidentatae, 10-20 parts of angelica sinensis, 10-30 parts of fructus forsythiae, 20-30 parts of ternate buttercup root and 5-15 parts of semen momordicae.
2. The compound astragalus polysaccharide granules disclosed by the invention in claim 1 are characterized by being prepared by the following steps:
(1) the astragalus, the honeysuckle, the isatis root, the angelica, the forsythia and the radix ranunculi ternate are respectively subjected to impurity removal and air drying, the standard weight is respectively weighed according to the formula, and the mixture is respectively crushed into coarse powder mixture with the granularity of 40-60 meshes for later use;
(2) weighing the achyranthes bidentata in a standard weight, and crushing the achyranthes bidentata into coarse powder with the granularity of 40-60 meshes for later use;
(3) removing shells of the semen momordicae, removing impurities by using semen momordicae, and weighing standard weight for later use;
(4) adding water into the mixture of the astragalus, the honeysuckle, the isatis root, the angelica, the fructus forsythiae and the radix ranunculi ternate in the step (1) for leaching for three times, soaking the mixture in water with the weight being 12 times that of the honeysuckle for 30-40 min for the first leaching, decocting the mixture for 1.5h with slow fire, and filtering the decoction to obtain a first filtrate; adding water with the weight being 10 times that of the mixture into the primary filtration dregs for secondary leaching, decocting the mixture for 1.5 hours with slow fire, and filtering the mixture to obtain a second filtrate; adding water with the weight 10 times that of the mixture into the residue obtained after the second filtration for carrying out third leaching, decocting with slow fire for 1h, filtering to obtain a third filtrate, combining the first filtrate, the second filtrate and the third filtrate, concentrating to obtain a concentrated solution with the ratio of 1:1, precipitating with absolute ethyl alcohol with the volume 4 times that of the concentrated solution, and drying the precipitate to obtain a mixture of astragalus polysaccharide and the like;
(5) adding water into the coarse achyranthes bidentata powder obtained in the step (2), leaching for 2 hours at 100 ℃ at a material-liquid ratio of 1:15, adding ethanol with the mass concentration of 95% and 5 times of the weight of achyranthes bidentata into the leaching solution, leaching for 2 times, each time for 2 hours, combining filtrates, concentrating, and drying to obtain achyranthes bidentata polysaccharide;
(6) pressing the semen momordicae in the step (3) in an extrusion type frost making machine, controlling the temperature to be 100 ℃, stopping pressing when the oil output reaches 17-20%, and crushing and uniformly mixing the medicine residues to obtain semen momordicae frost;
(7) fully mixing the extracts respectively prepared in the step (4), the step (5) and the step (6) to obtain an extraction mixture;
(8) pulping according to a granule preparation process, adding auxiliary materials into the extract mixture obtained in the step (7), and filling the mixture into a one-step low-temperature boiling granulator to prepare granules to obtain finished products, wherein the auxiliary materials are one or more than two of starch, sugar powder and dextrin.
3. The compound astragalus polysaccharide particle disclosed by the invention in claim 1 is characterized by comprising the following components in parts by weight: 20 parts of astragalus membranaceus, 10 parts of honeysuckle, 15 parts of isatis root, 10 parts of achyranthes bidentata, 10 parts of angelica sinensis, 10 parts of fructus forsythiae, 20 parts of ternate buttercup root and 5 parts of semen momordicae, and preparing a finished product according to the step of claim 2.
4. The compound astragalus polysaccharide particle disclosed by the invention in claim 1 is characterized by comprising the following components in parts by weight: 30 parts of astragalus membranaceus, 20 parts of honeysuckle, 35 parts of isatis root, 20 parts of achyranthes bidentata, 20 parts of angelica sinensis, 30 parts of fructus forsythiae, 30 parts of ternate buttercup root and 15 parts of semen momordicae are used as raw material medicaments, and a finished product is prepared according to the step of 2.
5. The compound astragalus polysaccharide particle disclosed by the invention in claim 1 is characterized by comprising the following components in parts by weight: 25 parts of astragalus membranaceus, 15 parts of honeysuckle, 25 parts of isatis root, 15 parts of achyranthes bidentata, 15 parts of angelica sinensis, 20 parts of fructus forsythiae, 25 parts of ternate buttercup root and 10 parts of semen momordicae are used as raw material medicaments, and a finished product is prepared according to the step 2.
6. The use of any one of claims 1 to 5, wherein the use comprises simultaneous administration of the above components and the content of the Chinese medicinal composition and heat-clearing and detoxifying Chinese medicaments or addition and subtraction of the components and the content on the basis of compatibility of the components.
7. The use according to claim 6, wherein the manufactured veterinary powder, veterinary soluble powder, veterinary oral solution, veterinary pill, etc. are within the scope of the present patent protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111275085.0A CN113855729A (en) | 2021-10-29 | 2021-10-29 | Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111275085.0A CN113855729A (en) | 2021-10-29 | 2021-10-29 | Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113855729A true CN113855729A (en) | 2021-12-31 |
Family
ID=78986262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111275085.0A Pending CN113855729A (en) | 2021-10-29 | 2021-10-29 | Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113855729A (en) |
-
2021
- 2021-10-29 CN CN202111275085.0A patent/CN113855729A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078399B (en) | Anti-virus pure traditional Chinese medicine preparation for livestock | |
| CN105287790B (en) | A kind of fevervine extract and its application | |
| CN101259160B (en) | Compound preparations for treating birdsvirosis and preparation thereof | |
| CN113855729A (en) | Compound astragalus polysaccharide granules for preventing and treating avian influenza of chickens | |
| CN104825700A (en) | Traditional Chinese medicine composition for resisting bacteria and diminishing inflammation | |
| CN114886961A (en) | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof | |
| CN104721337A (en) | Traditional Chinese medicine composition, preparation method and application thereof | |
| CN104825753B (en) | A kind of Chinese medicine composition for prevention newborn piglet diarrhea of being taken medicine by sow | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN113559137A (en) | Granulating method of veterinary drug granules | |
| CN111603514A (en) | Veterinary anti-mycoplasma infection traditional Chinese medicine compound preparation and preparation method and application thereof | |
| CN112089799A (en) | Compound preparation for treating chicken bronchial embolism and preparation method thereof | |
| CN101953987B (en) | Chinese medicinal composition for improving chicken immunity and preparation method thereof | |
| CN104758390A (en) | Botanical drug compound preparation for preventing and treating porcine diarrhea and preparation method thereof | |
| CN113940966B (en) | Callicarpa nudiflora composition for treating escherichia coli infection and preparation method and application thereof | |
| CN111544570B (en) | Antiviral preparation added with antibacterial peptide and preparation method thereof | |
| CN113750132A (en) | Compound astragalus polysaccharide soluble powder for preventing and treating avian influenza | |
| CN104288260B (en) | A kind of herbal medicine of effective preventing and treating porcine respiratory disease | |
| CN115531471B (en) | Composition for resisting African swine fever as well as preparation method and application thereof | |
| CN103479786B (en) | Traditional Chinese medicine composition for treating PRRS (Porcine Reproductive and Respiratory Syndrome) and preparation method and application thereof | |
| CN103479860B (en) | Traditional Chinese medicine composition for treating PRRS (Porcine Reproductive and Respiratory Syndrome) and preparation method and application thereof | |
| CN112618692B (en) | Traditional Chinese medicine composition for preventing and treating yellow and white scour of piglets as well as preparation method and application thereof | |
| CN103479789B (en) | Traditional Chinese medicine composition for treating PRRS (Porcine Reproductive and Respiratory Syndrome) and preparation method and application thereof | |
| CN109731044B (en) | Traditional Chinese medicine compound granule for treating intestinal infection of poultry and preparation method thereof | |
| CN108403866B (en) | Traditional Chinese medicine granule for preventing and treating avian influenza and improving chicken flock immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |